Boston Scientific Corporation (BSX) Stock Analysis & Winston Score
Boston Scientific makes medical devices — tools that doctors use to treat patients without major surgery. Its main products include stents (tiny tubes that keep arteries open), pacemakers, catheters, and devices that treat conditions like irregular heartbeats, chronic pain, and urological problems. The company sells primarily to hospitals and clinics around the world. Boston Scientific earns money by selling its devices directly to healthcare providers, with some recurring revenue from disposable components used in procedures. It operates globally, with significant sales in the United States, Europe, and Asia, and generates roughly $14 billion in annual revenue. The company's competitive position comes from its broad product portfolio, deep relationships with hospitals, and a large library of patents that make it hard for competitors to copy its designs. The key growth driver is an aging global population that will need more heart and other minimally invasive procedures over time, though the company faces ongoing risk from regulatory approvals, product liability lawsuits, and pricing pressure from hospital purchasing groups.
Winston Score: 66/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Good (17/30)
- Growth: Exceptional (19/20)
- Cash Flow: Exceptional (9/10)
- Stability: Strong (8/10)
- Valuation: Strong (8/10)
- Ownership: Weak (2/15)
Key Facts
Price: $44.03
Market Cap: $65.4B
Sector: Healthcare
Industry: Medical - Devices

